Vera Therapeutics, Inc. (VERA) Stock Price & Analysis

Vera Therapeutics, Inc. (VERA) closed at USD 30.94 on Wednesday, October 28, 2026, up 3.17% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 29.99; the Oct 28, 2026 session ranged USD 29.77–31.13 on volume of 1,277,484 shares. Market capitalization is $2.23B, with a 52-week range of USD 23.05–56.05 (NGM). Source: Nexqual, retrieved October 28, 2026 at 22:10 UTC.

Also available as compact Markdown for AI agents: nexqual.com/VERA.md

Key facts (VERA)

• Insider open-market sales, last ~7 months: 6 Form 4 filings, $5.7M; 0 not under a Rule 10b5-1 plan ($0K); 6 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.07 on a 1–5 scale) (15 analysts), mean target USD 74.2 (range 34–100).
• Total return with dividends: 1Y +5.4% vs S&P 500 +13.6%; 5Y +59.9% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD -1.61, revenue estimate $3.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VERA)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (VERA)

P/B 5.5x · FCF yield -15.20% · Earnings yield -18.03% · Net cash $424M · EV $1.81B

Insider sales (SEC Form 4, open-market, last ~7 months) (VERA)

6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (VERA)

Consensus Buy (mean 2.07 on a 1–5 scale), 15 analysts; mean target USD 74.2 (low 34, high 100).

Rating changes, last 120 days:

Total return (dividends reinvested) (VERA)

VERA earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

VERA recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

VERA suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

VERA company outlook (results filed Aug 10, 2026)

• “Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. • Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026. • Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026.”

Quoted word-for-word from the SEC 8-K results press release.

VERA analyst estimates and revisions

VERA options: expected move

Options price a move of about ±15.1% (±$4.55) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5.1% on average.

30-day implied volatility 67.5% vs 65.3% realized over the last 30 trading days. Put/call ratio (volume) 1.95. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 22:10 UTC)

Technical Analysis (VERA)

Nexqual's technical model rates VERA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 28, 2026 at 22:10 UTC.

Analyst Ratings (VERA)

Wall Street analysts rate VERA "Buy" based on 15 analysts, with a mean price target of USD 74.2 (range USD 34–100), per Nexqual as of October 28, 2026 at 22:10 UTC.

Earnings (VERA)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 22:10 UTC.

Financials & Fundamentals (VERA)

Source: Nexqual, October 28, 2026 at 22:10 UTC.

Financial Health Score (VERA)

Nexqual rates Vera Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 22:10 UTC.

Ownership (VERA)

Source: Nexqual, October 28, 2026 at 22:10 UTC.

Leadership (VERA)

Vera Therapeutics, Inc. is led by Marshall W. Fordyce, Founder, President, CEO & Director, per Nexqual as of October 28, 2026 at 22:10 UTC.

Major Backers & Investors (VERA)

Notable institutional backers of Vera Therapeutics, Inc. include Avoro Capital Advisors LLC, Price (T.Rowe) Associates Inc, Deep Track Capital, Lp, according to Nexqual as of October 28, 2026 at 22:10 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 22:10 UTC.

From Vera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe our expertise and track record will enable us to identify and acquire or in-license additional product candidates that represent opportunities to expand the potential value of our pipeline.

Legal & Regulatory Risks (Item 1A, quoted)

• Our business entails a significant risk of product liability and product liability claims could significantly harm our business, financial condition, results of operations and prospects.
• We may seek but fail to obtain orphan drug designations from the FDA or other regulatory authorities for our product candidates, and even where we have obtained such designations, we may be unable to receive or maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
• The terms of future potential marketing approvals for our product candidates and ongoing regulation regarding promotional activities and post-market obligations may limit how we manufacture and market products that are approved, and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.
• Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the patents and other proprietary rights of third parties. Claims by third parties that we infringe, misappropriate or otherwise violate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 22:10 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt